Literature DB >> 32190807

Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies.

Fang-Shu Ou1, Ming-Wen An2, Amy S Ruppert3, Sumithra J Mandrekar1.   

Abstract

With the launch of the National Cancer Institute's Precision Medicine Initiative in 2015, there has been a shift to trial designs that tailor health care solutions to individual patients by using a screening platform and by moving away from the one-trial/one-biomarker-at-a-time approach. To make precision medicine a reality, it is critical to identify and validate potential biomarkers to help select patients who will truly benefit from a targeted therapy. In this article, we discuss five trial designs: enrichment, umbrella, basket, subgroup, and window of opportunity. For each trial design, we describe the design characteristics, use ongoing or completed trials as case studies, provide any recent advances to the trial design, and discuss advantages and disadvantages of each design.

Entities:  

Year:  2019        PMID: 32190807      PMCID: PMC7079723          DOI: 10.1200/po.19.00051

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


  46 in total

Review 1.  Acute myeloid leukemia.

Authors:  B Löwenberg; J R Downing; A Burnett
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

2.  Novel Precision Medicine Trial Designs: Umbrellas and Baskets.

Authors:  Howard Jack West
Journal:  JAMA Oncol       Date:  2017-03-01       Impact factor: 31.777

Review 3.  Definitions and statistical properties of master protocols for personalized medicine in oncology.

Authors:  Lindsay A Renfro; Sumithra J Mandrekar
Journal:  J Biopharm Stat       Date:  2017-10-09       Impact factor: 1.051

Review 4.  Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.

Authors:  B Glimelius; M Lahn
Journal:  Ann Oncol       Date:  2011-01-13       Impact factor: 32.976

5.  Randomized phase III clinical trial designs for targeted agents.

Authors:  Antje Hoering; Mike Leblanc; John J Crowley
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

Review 6.  Bayesian clinical trials.

Authors:  Donald A Berry
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

7.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Authors:  Carsten Bokemeyer; Igor Bondarenko; Anatoly Makhson; Joerg T Hartmann; Jorge Aparicio; Filippo de Braud; Serban Donea; Heinz Ludwig; Gunter Schuch; Christopher Stroh; Anja H Loos; Angela Zubel; Piotr Koralewski
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

8.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

9.  Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

Authors:  Thomas J Lynch; Taral Patel; Luke Dreisbach; Michael McCleod; William J Heim; Robert C Hermann; Eugene Paschold; Nicholas O Iannotti; Shaker Dakhil; Steven Gorton; Virginie Pautret; Martin R Weber; Donald Woytowitz
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

10.  Comprehensive genomic characterization of squamous cell lung cancers.

Authors: 
Journal:  Nature       Date:  2012-09-09       Impact factor: 49.962

View more
  1 in total

1.  Biomarker Discovery and Validation: Statistical Considerations.

Authors:  Fang-Shu Ou; Stefan Michiels; Yu Shyr; Alex A Adjei; Ann L Oberg
Journal:  J Thorac Oncol       Date:  2021-02-02       Impact factor: 15.609

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.